Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, van Tellingen O, van de Ven M, Begthel H, Boj SF, Clevers H, Roodhart JML, Bos JL, Snippert HJG. Mertens S, et al. Among authors: proost n. Cell Rep. 2023 Apr 25;42(4):112324. doi: 10.1016/j.celrep.2023.112324. Epub 2023 Mar 30. Cell Rep. 2023. PMID: 37000626 Free article.
Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer.
Lõhmussaar K, Oka R, Espejo Valle-Inclan J, Smits MHH, Wardak H, Korving J, Begthel H, Proost N, van de Ven M, Kranenburg OW, Jonges TGN, Zweemer RP, Veersema S, van Boxtel R, Clevers H. Lõhmussaar K, et al. Among authors: proost n. Cell Stem Cell. 2021 Aug 5;28(8):1380-1396.e6. doi: 10.1016/j.stem.2021.03.012. Epub 2021 Apr 13. Cell Stem Cell. 2021. PMID: 33852917 Free article.
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Frank KJ, Mulero-Sánchez A, Berninger A, Ruiz-Cañas L, Bosma A, Görgülü K, Wu N, Diakopoulos KN, Kaya-Aksoy E, Ruess DA, Kabacaoğlu D, Schmidt F, Kohlmann L, van Tellingen O, Thijssen B, van de Ven M, Proost N, Kossatz S, Weber WA, Sainz B Jr, Bernards R, Algül H, Lesina M, Mainardi S. Frank KJ, et al. Among authors: proost n. Cell Rep Med. 2022 Nov 15;3(11):100815. doi: 10.1016/j.xcrm.2022.100815. Cell Rep Med. 2022. PMID: 36384095 Free PMC article.
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H. Kopper O, et al. Among authors: proost n. Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011202
Long-term expanding human airway organoids for disease modeling.
Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H. Sachs N, et al. Among authors: proost n. EMBO J. 2019 Feb 15;38(4):e100300. doi: 10.15252/embj.2018100300. Epub 2019 Jan 14. EMBO J. 2019. PMID: 30643021 Free PMC article.
SLC1A3 contributes to L-asparaginase resistance in solid tumors.
Sun J, Nagel R, Zaal EA, Ugalde AP, Han R, Proost N, Song JY, Pataskar A, Burylo A, Fu H, Poelarends GJ, van de Ven M, van Tellingen O, Berkers CR, Agami R. Sun J, et al. Among authors: proost n. EMBO J. 2019 Oct 4;38(21):e102147. doi: 10.15252/embj.2019102147. Epub 2019 Sep 16. EMBO J. 2019. PMID: 31523835 Free PMC article.
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S. Barazas M, et al. Among authors: proost n. Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10. Cancer Res. 2019. PMID: 30530501 Free PMC article.
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA, Kwon MC, Monkhorst K, Song JY, Bhaskaran R, Krijgsman O, Kuilman T, Peters D, Buikhuisen WA, Smit EF, Pritchard C, Cozijnsen M, van der Vliet J, Zevenhoven J, Lambooij JP, Proost N, van Montfort E, Velds A, Huijbers IJ, Berns A. Semenova EA, et al. Among authors: proost n. Cell Rep. 2016 Jul 19;16(3):631-43. doi: 10.1016/j.celrep.2016.06.020. Epub 2016 Jun 30. Cell Rep. 2016. PMID: 27373156 Free PMC article.
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J. Ratz L, et al. Among authors: proost n. Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y. Breast Cancer Res. 2022. PMID: 35715861 Free PMC article.
29 results